Of note, MDA-MB-231 and MDA-MB-468 cells are representative of the triple-negative breast cancer clinical subtype (negative for hormone receptor and HER2 expression), which is associated with a poor prognosis and a more aggressive phenotype. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.